Altimmune Q3 2026 Earnings Date & Estimates

Altimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity and liver diseases. The company’s research programs are designed to address metabolic and inflammatory conditions with significant unmet medical needs.

Altimmune’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being evaluated for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company has also developed earlier-stage vaccine and immunotherapy programs, including candidates targeting infectious diseases and chronic hepatitis B.

Altimmune is based in Gaithersburg, Maryland, and its clinical development activities are conducted through studies involving patients in the United States and other regions. The company was formerly known as Vaxin, Inc. and adopted the Altimmune name as it expanded its focus toward immunotherapeutics and metabolic disease treatments. Vipin K. Garg has served as the company’s president and chief executive officer.